Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Heat Biologics, Inc.

  • Jeffrey Wolf, Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ ''Killer'' T-cells. Our T-Cell Activation Platform (TCAP) produces therapies designed to turn ''cold'' tumors ''hot'' and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Our ComPACT™ technology is a dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We are currently enrolling patients in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies.

  • Date:Monday, February 11
  • Time:11:00 AM - 11:15 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23391
  • Goal for Presentation:To increase awareness of Heat Biologics.
  • Company Website:www.heatbio.com
  • Company HQ City:Durham
  • Company HQ State:North Carolina
  • Company HQ Country:United States
  • Ticker:HTBX
  • Exchange:NASDAQ
  • CEO/Top Company Official:Jeffrey Wolf
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:HS-110
  • Development Phase of Primary Product:Phase II
Speakers
Jeffrey Wolf
Heat Biologics, Inc.
Back